DEBIOS DX
Invest in the future of renal diagnostics
Say goodbye to renal biopsies. Say welcome FIBROKIT.
Discover how our first product FIBROKIT will impact +800 million people lifes.
DEBIOS is a huge opportunity
DEBIOS introduces FIBROKIT, the first worldwide patented non-invasive test for diagnosing renal fibrosis using a simple urine sample. This groundbreaking technology has the potential to greatly reduce reliance on invasive biopsies in diagnosing and managing Chronic Kidney Disease (CKD) and kidney transplanted patients.
Say goodbye to renal biopsies. Welcome FIBROKIT.
An Investment Opportunity
Why invest in DEBIOS?
Growing Market: Renal diagnostics market projected at $8.3 billion by 2035, with an annual growth rate of 7.6%.
High Recurrence and Scalability: 94% of key opinion leaders indicate they would use FIBROKIT twice/year per patient for CKD patients and post-kidney transplants.
Global Impact: CKD affects over 800 million people; early detection through FIBROKIT can significantly improve treatment options and quality of life.
Our seed round is open
The product: FIBROKIT
Two versions for B2B and B2B2C
FIBROKIT-ELISA: Precision diagnostics for hospitals and labs, ideal for advanced monitoring.
FIBROKIT-Lateral Flow (LF): Rapid test for use in point-of-care settings, such as pharmacies, ideal for mass screening of at-risk populations
1.15 million € seed round for 2025-2026
Clear milestones until CE/FDA approval and commercialization
Estimated Exit 2029
Multiply your investment by 7X
Tax deductions available
Investment minimum ticket 2.500 EUR
Join biotech professional VC investors now
Fibrokit will absolutely revolutionize the CKD patient's management and kidney transplantations.
Dr. Jordi Bover
Head of nephrology at Hospital Universitari Germans Trias i Pujols
94% of Key Opinion Leaders in nephrology will use FIBROKIT on every patient
Request access to our investor dataroom
Sign up for one of our webinar sessions to learn more about this opportunity.